Overexpression of the membrane mucin MUC4/Sialomucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies. As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells. SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the eect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC upregulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not signi®cantly increase proliferation of A375 cells in vitro. Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors. These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis. Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic eect of SMC is independent of tumor-host interactions. These ®ndings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the ®rst time evidence for the regulation of programmed cell death by a gene of the MUC family. Oncogene (2001) 20, 461 ± 470.
Introduction
Mucins are characteristic products of vulnerable epithelia and serve as a primary mechanism for their protection (Strous and Dekker, 1992) . Mucins are also associated with carcinomas (Bhavanandan, 1991) , but there is little information about the functions of these mucins in tumors and whether they contribute to malignancy. The best evidence for a role for mucins in tumor progression comes from studies of the membrane mucins MUC1 and MUC4, in which mucin expression has been shown to reduce cell ± matrix and cell ± cell adhesion (Wesseling, 1995; Komatsu et al., 1997) and block immune cell killing of mucinexpressing tumor cells (van de Wiel-van Kemenade et al., 1993; Komatsu et al., 1999) . A second function attributed to membrane mucins is an involvement in cellular signaling . MUC1 has cytoplasmic tyrosine residues which can be phosphorylated (Zrihan-Licht et al., 1994) to recruit signaling components from the cytoplasm (Pandey et al., 1995) . MUC4 has two EGF-like domains, one of which can apparently act as an intramembrane ligand/ modulator for the receptor tyrosine kinase ErbB2 (Carraway et al., 1999b) . How these signaling functions contribute to epithelial or carcinoma cell behavior is unknown.
The rat homolog of MUC4 was originally isolated from ascites 13762 rat mammary adenocarcinoma cells and is called sialomucin complex (SMC) or ASGP-1/ ASGP-2 . Muc4/SMC is encoded by a single gene (Sheng et al., 1992; Wu et al., 1994a; Moniaux et al., 1999) and post-translationally processed into two subunits, ASGP-1 and ASGP-2 Sheng et al., 1990) . Highly O-glycosylated mucin subunit ASGP-1 has a typical mucin-type rigid and extended structure . The transmembrane subunit ASGP-2, which anchors the complex to the cell surface, contains two EGF-like domains, EGF-1 and EGF-2 (Sheng et al., 1992) . Notably, EGF-1 domain bears all of the consensus amino acid residues for active EGF-like ligands (Sheng et al., 1992; Carraway et al., 1992) , and its sequence is highly conserved (80%) between human (Moniaux et al., 1999) , mouse (unpublished) and rat (Sheng et al., 1992) , suggesting a possible active ligandlike function of this domain . Importantly, the ASGP-2 subunit forms a stable complex with the receptor tyrosine kinase ErbB2/neu, but not ErbB1, ErbB3 or ErbB4, when Muc4/SMC and the receptor are expressed in the same cell (Carraway et al., 1999b) . Up-regulation of Muc4/ SMC expression in transfected A375 melanoma cells resulted in potentiation of ErbB2 phosphorylation in response to heregulin ligand (Carraway et al., 1999b) . Furthermore, complexes of Muc4/SMC and ErbB2 in 13762 ascites tumor cell membranes are associated with other cellular signal transducers, including elements of the Ras to MAPK signaling pathway (Carraway et al., 1999a) .
Muc4/SMC has also been linked to mammary cancer (Komatsu et al., 1999) . In the highly invasive and metastatic ascites subline MAT-B1 and MAT-C1 cells of the 13762 rat mammary adenocarcinoma, Muc4/ SMC gene is ampli®ed and overexpressed to provide up to 1% of total cellular protein Wu et al., 1994b) . In less aggressive 13762 solid tumors expression of Muc4/SMC was much lower (Huggins et al., 1980) . Moreover, studies in human breast carcinomas demonstrated that aggressive cancer cells found in patient eusions are frequently accompanied by the overexpression of Muc4 (Komatsu et al., 1999) . These ®ndings suggest that the deregulation of Muc4/SMC expression facilitates the development and progression of mammary cancer in both humans and rodents. This hypothesis is supported by studies on mammary epithelial cells showing that Muc4/SMC expression is regulated by associations with extracellular matrix (Price-Schiavi et al., 1998) and by the growth factor TGFb (Price-Schiavi et al., 1998 . Both matrix interactions (Boudreau and Bissell, 1998) and TGFb responsiveness (Arteaga et al., 1996) are lost during breast cancer progression.
To address possible functions of Muc4/SMC in tumor cell behavior, we have developed a tetracyclineregulatable construct of the rat Muc4/SMC gene and transfected it into dierent tumor cell lines (Komatsu et al., 1997) . Studies on transfected A375 melanoma cells have been particularly instructive, showing that Muc4/SMC expression can block cell ± matrix and cell ± cell interactions (Komatsu et al., 1997) , reduce killing of the tumor cells by lymphokine-activated killer cells (Komatsu et al., 1999) and potentiate metastasis , all functions which can be attributed to the anti-recognition eects of the mucin subunit. Here, we examined the eect of Muc4/SMC overexpression on primary tumor growth and tumor burden. Muc4/SMC-transfected A375 melanoma cells were injected subcutaneously into the¯ank of nude mice, and local tumor growth was compared between tumors in which the Muc4/SMC was up-regulated vs down-regulated, using the tetracycline inducible expression system in vivo. Upregulation of Muc4/SMC expression accelerates growth of A375 tumor in the host animal. Further, in vitro studies suggested that this eect was not due to the increased proliferative potential of A375 cells, but was rather due to the suppression of apoptosis. These studies provide the ®rst evidence for repression of apoptosis via changes in expression of a mucin. Since loss of adhesion is usually associated with increased apoptosis of epithelial cells and carcinomas, this unexpected activity of Muc4/SMC likely resides in another part of the molecule, possibly in signals deriving from the EGF domains.
Results

Effect of SMC expression on tumor growth
In recent studies we have described the potentiation of metastasis by SMC in the transplanted A375 melanoma in nude mice . In those experiments SMC was regulated in vivo using a tetracycline responsive promoter (tet-o system). To further investigate the contribution of SMC in malignancy, we have now studied the eect of in vivo up-regulation of SMC on the growth of primary tumor. The SMC-transfected A375 cells were transplanted s.c. into nude mice at the¯ank, and tumor growth rate was compared with the dierent tetracycline treatments. In the ®rst set of experiments, transfectants with repressed expression of SMC (O) were injected into mice which had been supplied with tetracycline-containing drinking water for 7 days, and the mice continued to receive the tetracycline therapy. Alternatively, transfectants with the SMC overexpression (On) were injected into the mice without the tetracycline therapy. SMC expression levels in the local tumors are reduced 50 ± 100-fold by tetracycline administration (Figure 1a inset ). Most importantly, A375 tumor with SMC overexpression (On) grows at a substantially increased rate compared to the SMC-O tumor ( Figure 1a ). In contrast, the growth of parental A375 tumor was not aected by the tetracycline treatment ( Figure 1b) . To show that this eect on tumor growth is not dependent on the site of tumor injection, we have repeated these experiments using injections into the footpad, a site we previously used for demonstrating metastasis from primary tumor . SMC overexpression also induced accelerated tumor growth at this site (data not shown).
Cultured A375 cells were used in these experiments. Another question is whether SMC can potentiate growth from more advanced tumors. To address this question, we isolated SMC-transfected A375 cells from a lobular tumor mass which developed in the abdominal cavity following s.c. injection of SMCtransfected A375 cells (O) and the induction of SMC overexpression (O?On). These metaSC-1 cells were grown in the animal over a period of 2 months, and thus were selected for their ability to grow in vivo as metastases before being used for this study. In culture, these cells are adherent to plastic dishes and grow in growth medium containing tetracycline as well as the selection drugs G418 and Hygromicin. They respond to the removal of tetracycline by the induction of SMC overexpression (Figure 2a) , followed by loss of cell adhesion (Komatsu et al., 1997) , indicating that they are the SMC-transfectants which metastasized from the local subcutaneous tumor. For the present study, these metaSC-1 cells (SMC-O) were injected into the tetracycline-treated mice at a dosage of 1610 5 cells/ animal to examine the eect of SMC up-regulation on their growth in vivo. The mice were divided into two groups; SMC overexpression was induced in group 2 on day 6 by terminating tetracycline therapy as described previously . The tumor growth rate of the group 2 mice, which stopped receiving tetracycline therapy, was signi®cantly increased over the growth rate of group 1 mice ( Figure  2b ). The tumor growth curve of the group 2 mice 5 cells/animal into 10 nude mice which were undergoing tetracycline therapy. After 6 days, tetracycline administration was stopped for ®ve mice to induce SMC overexpression in the transplanted tumor (indicated by the arrow). The other ®ve mice were continued on the tetracycline therapy. Tumor volume for the two groups was calculated as described in Materials and methods. The accelerated tumor growth upon SMC induction was also observed in similar experiments in which mice received 1610 6 tumor cells (data not shown) began to separate from the growth curve of the group 1 mice around day 10. Since the tetracycline-regulated gene expression in vivo is expected to reach maximum at 4 ± 10 days after the end of tetracycline therapy (Passman and Fishman, 1994; Dhawan et al., 1995) , our data indicate that tumor growth becomes accelerated upon induction of SMC overexpression. Overall, these results demonstrate a pronounced eect of SMC on in vivo tumor growth, suggesting that SMC can play a role as a tumor growth-promoting agent in vivo in tumor progression.
Effect of SMC on proliferation of A375 cells
The change in size of a tumor mass is a net outcome of the increase in the tumor cell number due to proliferation and the decrease due to the tumor cell death (necrosis/apoptosis) caused by environmental stresses such as the lack of nutrient/growth factors/ oxygen or by immune destruction. Tumor expansion and cell death are often in¯uenced by tumor-host interactions, e.g. matrix metalloproteinase secretion from stromal cells and neovascularization induced by the tumor derived factors. We therefore sought to clarify whether the SMC-induced rapid tumor growth is due to intrinsic proliferative or apoptotic behavior of SMC-bearing cells or to the eect of SMC overexpression on host-tumor interactions. First, we analysed proliferation of SMC-transfectants in vitro at the dierent SMC expression levels ( Figure 3a) . SMC-On and O cells showed a similar rate of anchorage independent growth in semisolid agarose culture in complete growth media containing 10% fetal calf serum (Figure 3b ). At low concentrations of serum (0.1 and 0.5%), SMC-On cells had a slightly increased (*20%) cell number compared to SMC-O cells after 4 days in culture (data not shown). However, at these low concentrations of serum, cell apoptosis signi®-cantly reduced the number of viable cells in the SMC-O cultures, as described below, complicating the analyses of cell proliferation. Likewise, by cell cycle analyses, the fraction of cells in the S and G2/M phases was found to be only slightly greater in SMC-On cells than in SMC-O cells during incubation in low serum ( Table 1 ), suggesting that SMC expression does not have a signi®cant mitogenic eect, if any, on A375 cells. Thus, SMC expression in the A375 cells has only modest eects on cell proliferation and growth in vitro. Similarly, no consistent evidence for an in vivo proliferation response to SMC could be observed in the A375 tumors using immunocytochemical analyses for Ki67 (data not shown).
Effect of up-regulation of SMC on tumor apoptosis in vivo
Another intrinsic property of cancer cells which critically contributes to rapid tumor expansion is an ability to resist apoptosis. Acquisition of this ability is a rate-limiting step in the sequential progression from a hyperplastic angiogenic lesion to malignant cancer (Hanahan et al., 1996) . The possible involvement of SMC in regulation of tumor apoptosis was tested in situ by TUNEL staining of tumor sections. In studies cited above, we have demonstrated rapid growth of SMCexpressing tumors when injected into either the¯ank or footpad of nude mice. The footpad tumors are more con®ned to their local site and were used for these studies of apoptosis in the primary tumor. Formalin®xed paran-embedded sections were prepared from these tumors and utilized for analyses of both SMC expression (Figure 4a ± c) and apoptosis (Figure 4d ± f) . TUNEL staining revealed that the level of apoptosis was greatly reduced by up-regulation of SMC expression (Figure 4d ,e). For quantitative comparisons of apoptosis levels in these tumors, the most apoptotic area in each tumor section was selected, and the number of TUNEL-positive cells were counted in a given ®eld (0.860.6 mm). SMC-overexpression in these tumors resulted in 480% reduction of the frequency of apoptotic cells (Figure 4g ). These observations demonstrated that SMC up-regulation suppresses apoptosis and facilitates the survival of A375 tumor in vivo.
SMC suppression of apoptosis in vitro
Given its potent eects on cell ± extracellular matrix and cell ± cell adhesions (Komatsu et al., 1997) , overexpression of SMC should aect the interaction between tumor and stroma. Moreover, susceptibility of tumor cells to immune destruction is greatly reduced by SMC expression (Komatsu et al., 1999) . Furthermore, SMC up-regulation might increase secretion of angiogenic factors or matrix metalloproteinases. Therefore, SMC-dependent suppression of tumor apoptosis might be mediated by altered tumor ± stroma interactions. To test this possibility, we analysed the apoptosis levels of A375 cells in vitro upon serum starvation. SMC overexpression was induced, and cells were incubated in serum-free DMEM for 24 h. The levels of apoptosis was determined by Annexin-V and propidium iodide staining, followed by FACScan analyses. As shown in Figure 5a ,b, apoptosis in serum-starved cells was reduced nearly 80% upon SMC up-regulation. Apoptotic levels of control A375 cells co-transfected with an empty tetOp vector and transactivator gene were not altered by the tetracycline treatment, demonstrating that SMC expression is responsible for the observed suppression of apoptosis (Figure 5c,d) . Further, the level of DNA fragmentation was also shown to be reduced substantially in the SMC-induced cells (14% of SMC-O cells) after 24 h of serum starvation (Figure 6 ), providing further evidence for the anti-apoptotic/pro-survival eect of SMC. These combined results show that up-regulation of SMC enhances the survival of A375 cells in culture, indicating that suppression of tumor apoptosis by SMC is independent of tumor-host interactions and that resistance to apoptosis is an intrinsic property of SMC-bearing tumor cells. Importantly, these ®ndings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival.
Muc4 suppression of tumor cell apoptosis M Komatsu et al
SMC effect on PARP cleavage
Caspases play central roles in various apoptotic pathways. To begin to address the mechanism involved in SMC-mediated modulation of programmed cell death, we examined a caspase cleavage product poly(adenosine diphosphate ribose) (PARP) in the serum-starved cells. Immunoblot analyses with anti-PARP mAb demonstrated that the cleavage of PARP is reduced in SMC-overexpressing cells (Figure 7) , suggesting the down-regulation of caspase3 and/or caspase9 in these cells (Duriez and Shah, 1997) . These observations are in agreement with the ®ndings described above and suggest that regulation of these caspase activities is at least one of the targets for SMCpromoted cell survival signaling.
Discussion
In our previous studies, we described multi-functional properties of SMC contributing to development of malignancy by modulation of cell adhesion and immune recognition (Komatsu et al., 1997 (Komatsu et al., , 1999 . The ®ndings described in this report add yet another aspect to the list of multiple functions of this mucin gene: suppression of apoptosis. Overexpression of SMC suppresses apoptosis of xenotransplanted A375 melanoma and promotes rapid tumor growth in host animals. Thus, the present study provides for the ®rst time direct evidence for regulation of apoptosis by a gene of the MUC family. An ability to down-regulate apoptosis is an important feature of some progressive tumors, and acquisition of this ability appears to be a rate-limiting step for the malignant conversion of neoplastic lesions (Hanahan et al., 1996) . Up-regulation of SMC expression, therefore, can critically contribute to tumor progression through its antiapoptotic function. The eect of SMC overexpression is unique in that it diminishes both cell adhesion and apoptosis simultaneously. In general, cell adhesion and apoptosis are two counteracting events. Cell adhesion to extracellular matrix is required for the growth factor-dependent cell cycle progression in ®broblasts (Assoian, 1997) and for the survival of endothelial as well as epithelial cells (Meredith, 1993) . In mammary gland, programmed cell death induced by the loss of integrin-dependent adhesion (anoikis) is mediated by extracellular matrixdegrading matrix metalloprotease activities and is a principal mechanism of mammary involution (Talhouk et al., 1992; Boudreau et al., 1995) . Programmed cell death in the absence of proper cell adhesion would prevent invasion or metastasis, implying that tumorigenesis requires escape from this control mechanism (Meredith and Schwartz, 1997) . The signi®cance of these survival activities of this molecule may be explained by its unique domain structures. As a complex of two distinct subunits, SMC contains a large mucin type sequence in ASGP-1 (Komatsu et al., 1997) and an ErbB2-ligand domain in ASGP-2 (Carraway et al., 1999b) . We suggest that presence of these discrete and distinct domain structures could allow this molecule to have two counteracting functions in one molecule; ASGP-1 inhibits cell adhesion sterically, and ASGP-2 inhibits apoptosis through ErbB2/neu signaling. In support of this view, ASGP-2 and ErbB2/neu form a stable complex in A375 cells, resulting in an enhanced autophosphorylation of ErbB2/neu and ErbB3 (Carraway et al., 1999b) . Thus, it will be of interest to explore the possible regulatory relationship between signaling from the ASGP-2/ErbB2 complex and apoptosis. A potential role for this complex in human cancer is suggested by the fact that the human counterpart Muc4 also contains EGF-like domains, which share *80% homology to those of rat SMC (Moniaux et al., 1999) . MUC4-HER2/neu complex has been detected in human tissues where the two proteins are co-expressed, e.g. conjunctiva and cornea (unpublished observation). Although other human tissues, such as lactating mammary gland, have not been tested for the MUC4-HER2/neu complex, we observed co-expression of the two molecules in advanced breast cancer patients (Komatsu et al., 1999) . Regardless of the pathway, suppression of apoptosis by Muc4/SMC may be an important feature of tumorigenesis in mammary gland, in which cell adhesion and apoptosis regulate normal physiology. While anoikis causes involution, decreased cell adhesion appears to promote ductal branching during mammary gland development (Sympson et al., 1994) . Therefore, it will be interesting to test transgenic models for the eect of SMC up-regulation on mammary gland development, involution, and tumorigenesis. In addition to the involvement in intracellular signaling via ASGP-2/ErbB2 complex formation, SMC is likely to aect the signaling by modulation of cell adhesion. The anti-adhesive eect of SMC is not necessarily limited to the promotion of tumor cell release or escape from immune recognition. It may also impact signaling through altering cytoskeletal structure, cell stretching, and adhesion-regulated kinase activities and gene expression. For instance, Muc4/SMC overexpression may cause genomic instability in tumor cells due to the absence of adhesion-dependent genomic maintenance (Tlsty, 1998) . That such eects may facilitate emergence of a more malignant phenotype has been demonstrated in other carcinogenesis models (Tlsty, 1998) . Regardless of the mechanism, it is likely that Muc4/SMC contributes to tumor progression by virtue of its ability to aect cellular signaling. In this respect, Muc4/SMC may function in tumorigenesis similarly to matrix metalloproteinases. It has been reported that degradation of extracellular matrix and cell adhesion molecules by matrix metalloproteases alters integrin-and cadherin-mediated signaling and induces aberrant cell behavior, such as epithelialmesenchymal conversion (Lochter et al., 1997) and tumorigenesis (Sternlicht et al., 1999) in some systems. It is reasonable to suspect that up-regulation of Muc4/ SMC will lead to similar biological consequences. Resolution of these issues awaits further investigations.
Materials and methods
In vivo tumor growth analyses A375 melanoma cells transfected with an inducible expression of SMC (Rep8) were described previously (Komatsu et al., 1997 . These transfectants were maintained at conuence in DMEM supplemented with 10% fetal calf serum (FCS), 2 mg/ml tetracycline, 0.5 mg/ml G418, 0.3 mg/ml Hygromicin. SMC overexpression was induced by removal of tetracycline (Tet-O system) from the culture as described before (Komatsu et al., 1997) . For the analyses of in vivo tumor growth, female nude mice were purchased from Taconic (Germantown, NY, USA) at age 4 ± 5 weeks and used at 6 weeks of age. SMC-repressed (O) and induced (On) cells were inoculated s.c. at 1610 5 or 1610 6 cells/ animal into the¯ank of mice which had been fed with or without 1 mg/ml tetracycline in the drinking water, respectively . Tumor growth was monitored twice a week, and diameter of the local tumor was measured using calipers. 
Determination of SMC expression
In vitro expression levels of SMC were determined by FACScan analyses. Cells from subcon¯uent cultures were detached gently from the plates by treating with phosphatebuered saline (PBS)-based, EDTA-containing dissociation buer (GIBCO ± BRL). Cells were then washed 2 ± 3 times with PBS and resuspended in 3% BSA in PBS. Subsequently, cell suspensions were incubated with anti-SMC mAb, 4F12 (Rossi et al., 1996) , followed by the incubation with FITCconjugated goat anti-mouse IgG secondary antibodies (Sigma). The¯uorescence intensity was determined by FACScan analysis.
The in vivo SMC expression was analysed by FACScan analyses and immunohistochemical staining of paran sections using anti-SMC mAb 4F12. For FACScan analyses, tumors were excised from animals and minced on a Petri dish in Dulbecco's PBS saline without calcium. They were then treated with dissociation buer (GIBCO ± BRL) at 378C for 15 min. Dissociated cells were rinsed in PBS and passed through a 70 mm strainer before staining with the monoclonal antibody and FITC-conjugated secondary antibodies.
For in situ analyses, formalin-®xed paran-embedded tumor sections (5 mm) were prepared from excised tumors and immunohistochemically stained with 4F12 mAb as described previously . Brie¯y, the tumor sections were deparanized in xylene and hydrated in absolute ethanol followed by successive immersions in a graded series of ethanol-water. Antigenic sites were retrieved from ®xed samples using DAKO Retrieval Solution (DAKO, Carpinteria, CA, USA) for 20 min. Sections were rinsed in PBS, then treated with 3% (v/v) H 2 O 2 to inhibit endogenous peroxidases. The sections were incubated with 4F12 mAb in DAKO antibody diluent, rinsed with PBS and treated with DAKO LINK Reagent for 30 min. After a PBS rinse, samples were incubated for 30 min in streptavidin peroxidase, rinsed with PBS and incubated with DAKO substratechromagen solution. Sections were rinsed in tap water, 
In vitro cell growth analyses
The proliferative potential of SMC transfectants was examined by measuring cell cycle progression in low serum as well as colony formation eciency in soft agarose. SMCtransfectants were induced for SMC overexpression 2 ± 3 days prior to each assay. For colony formation assays, SMC-On and O cells were harvested after incubation with trypsin-EDTA, and washed once with complete media and twice with PBS. Cell suspensions were ®ltered through a 40 mm cell strainer (Becton Dickinson, NJ, USA) to remove any clumps of cells. Cells were then seeded in 6-well plates at 500 cells/ well (duplicate) and cultured for 12 days in 0.3% semisolid agarose in DMEM containing 3% FCS with or without tetracycline. Colonies with a diameter greater than 125 mm were counted.
For cell cycle analyses, the transfectants (SMC-On and -O) were incubated in DMEM supplemented with 1% FCS for 2 days. Cells were then dissociated into single cells with trypsin-EDTA, seeded onto agarose-coated 6-well plates at 1610 5 cells/well, and cultured for 48 h in suspension in 0.9% methylcellulose-containing media (StemCell Technologies, Vancouver, BC, Canada) supplemented with 1 or 0.5% FCS with or without 2 mg/ml tetracycline. Following methylcellulose digestion (1 U cellulase/ml of culture, Sigma), cells were harvested, rinsed in PBS, and ®xed with cold 70% ethanol overnight. Fixed cells were stained with propidium iodide for the quantitation of DNA content. Fraction of the cell population in each stage of the cell cycle was determined by FACScan analysis. In the control experiment, tetracycline treatment of parental A375 cells did not aect the cell cycle or colony formation of these cells. A representative of three independent experiments is shown.
In situ analyses of tumor apoptosis
To determine the apoptotic levels of tumors, TUNEL assays were performed on paran-embedded tumor sections using the DeadEnd TM Apoptosis Detection System (Promega, Madison, WI, USA) according to the manufacturer's manual. The most apoptotic region of each section was chosen, and the number of apoptotic cells in a given ®eld (0.860.6 mm) was counted for quantitative analysis. Several discrete sections were examined for each tumor. Tumors from ®ve dierent animals were examined for each experimental group of mice.
Annexin/propidium iodine staining
Cells were cultured for 24 h in serum-free DMEM medium supplemented with 0.1% BSA w/v. After the serum starvation, cells were harvested with dissociation buer (GIBCO ± BRL), counted and 1*2610 5 cells placed in each tube. The level of apoptosis was determined using ApoAlert TM Annexin V Apoptosis Kit (Clontech, Palo Alto, CA, USA). Brie¯y, the cells were washed and resuspended in 200 ml annexin binding buer (Clontech), and incubated with 5 ml annexin V-FITC (20 mg/ml) and 5 ml propidium iodide (50 mg/ml) for 15 min. The level of staining was then determined by FACScan analyses. The A375 cells cotransfected with an empty tetOp vector (without SMC cDNA) and a transactivator gene were used as controls.
DNA fragmentation assay
The level of apoptosis-induced DNA fragmentation was determined using the Cell Death Detection ELISA Kit (Boehringer Mannheim, Germany). Cells were starved for serum as above, and 5610 4 cells were lysed in the lysis buer supplied by the manufacturer. To determine the cytoplasmic histone-associated DNA fragments, an ELISA assay was performed using anti-histone mAb in a 96-well plate following the manufacturer's instructions. Absorbance at 405 nm was measured for serum-starved as well as nonstarved (control) cell samples, and the Abs. 405 value of control cells was subtracted from that of serum-starved cells to determine apoptosis-induced DNA fragmentation.
PARP Western blot
Cells were cultured for increasing lengths of time in serumfree medium supplemented with 0.1% BSA w/v. After an appropriate length of time, cells were lysed in the SDS lysis buer containing 62.5 mM Tris/HCl, pH 6.8, 6 M Urea, 10% glycerol, 2% SDS, 0.00125% bromophenol blue and 5% bmercaptoethanol. The lysates were then sonicated for 10 s on ice and incubated in a water bath at 658C for 15 min. Samples were run on an 8% SDS ± PAGE followed by immunoblotting with anti-PARP mAb (Ab-2 Oncogene Research Products, CA, USA) and goat anti-mouse IgG secondary antibodies (PIERCE, Rockford, IL, USA). Full length PARP was detected as a 115 kDa band. The apoptosis-related cleavage fragment of PARP was approximately 85 ± 90 kDa.
